- Trials with a EudraCT protocol (98)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (7)
98 result(s) found for: Bicalutamide.
Displaying page 1 of 5.
EudraCT Number: 2015-001634-17 | Sponsor Protocol Number: 2015.0704 | Start Date*: 2015-12-24 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: 18FDHT-PET to visualize the effect on the androgen receptor level by bicalutamide | ||
Medical condition: androgen receptor positive metastatic breast cancer patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-000422-39 | Sponsor Protocol Number: 8669-002 | Start Date*: 2009-01-14 | |||||||||||
Sponsor Name:MSD | |||||||||||||
Full Title: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of Bicalutamide With or Without Deforolimus in Men With Asymptomatic, Metastatic Castrate-Res... | |||||||||||||
Medical condition: Metastatic prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: SE (Completed) NL (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) DK (Completed) GB (Prematurely Ended) BE (Completed) DE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003190-96 | Sponsor Protocol Number: SHR-3680-III-HSPC | Start Date*: 2020-02-10 | ||||||||||||||||
Sponsor Name:Jiangsu Hengrui Pharmaceuticals Co., Ltd. | ||||||||||||||||||
Full Title: One multicenter, randomized, open, phase III clinical study on SHR3680 combined with androgen deprived therapy (ADT) versus Bicalutamide combined with ADT in treatment of metastatic hormone-sensiti... | ||||||||||||||||||
Medical condition: Metastatic hormone-sensitive prostate cancer with high tumor load | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: CZ (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021868-15 | Sponsor Protocol Number: 9785-CL-0222 | Start Date*: 2011-07-25 | |||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. (APGD) | |||||||||||||
Full Title: A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 (ASP9785) vs. Bicalutamide in Castrate Men with Metastatic Prostate Cancer | |||||||||||||
Medical condition: Metastatic Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) DE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000384-10 | Sponsor Protocol Number: D6873C00047 | Start Date*: 2005-03-15 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: An Open-label, non-comparative, multi-centre study to assess the efficacy and safety of bicalutamide when used in combination with anastrozole for the treatment of gonadotropin-independent precocio... | |||||||||||||
Medical condition: testotoxicosis (familial male-limited gonadotropin-independent precocious puberty) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003847-22 | Sponsor Protocol Number: ICORG11-04 | Start Date*: 2012-02-02 | |||||||||||
Sponsor Name:ICORG | |||||||||||||
Full Title: ECOG 2809: Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy | |||||||||||||
Medical condition: Patients with Rising PSA at high risk of Prostate cancer progression | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001180-77 | Sponsor Protocol Number: D6873C00047 | Start Date*: 2012-03-07 | |||||||||||
Sponsor Name:AstraZeneca | |||||||||||||
Full Title: An open-label, non-comparative, multi-centre study to assess the efficacy and safety of bicalutamide when used in combination with anastrozole for the treatment of gonadotropin-independent precocio... | |||||||||||||
Medical condition: testotoxicosis (precocious puberty) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002122-67 | Sponsor Protocol Number: 1211 | Start Date*: 2013-12-05 | |||||||||||
Sponsor Name:EORTC | |||||||||||||
Full Title: Phase II randomized comparative trial of TAK-700 (Orteronel) versus bicalutamide in metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castration. | |||||||||||||
Medical condition: metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: BE (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004338-26 | Sponsor Protocol Number: FE200486 CS28 | Start Date*: 2008-11-18 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: Ensayo clínico abierto, aleatorizado, de grupos paralelos que compara degarelix frente a bloqueo androgénico combinado (goserelina + bicalutamida) en términos de reducción de la puntuación en la es... | |||||||||||||
Medical condition: Cáncer de próstata | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: ES (Completed) GB (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001891-35 | Sponsor Protocol Number: D4200C00080 | Start Date*: 2007-06-22 | |||||||||||
Sponsor Name:AstraZeneca SAS | |||||||||||||
Full Title: A randomized, double-blind phase II trial to assess the efficacy and safety of bicalutamide (Casodex® ) associated to ZD6474 (Zactima™ ) or to placebo in patients with castration-refractory metasta... | |||||||||||||
Medical condition: Metastatic prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005232-33 | Sponsor Protocol Number: FE200486 CS30 | Start Date*: 2009-04-15 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients o... | |||||||||||||
Medical condition: Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) FR (Completed) ES (Completed) GB (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001128-38 | Sponsor Protocol Number: pVAX/rhPSA -EP 2006 | Start Date*: 2008-09-30 |
Sponsor Name:Uppsala University Hospital | ||
Full Title: DNA Vaccine Coding for the Rhesus Prostate Specific Antigen (rhPSA) and Electroporation in Patients with Relapsed Prostate Cancer. A Phase I/II Study | ||
Medical condition: Patients with relapse of prostate cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-000299-15 | Sponsor Protocol Number: BC1-03 | Start Date*: 2004-11-03 |
Sponsor Name:Algeta AS | ||
Full Title: A double-blind, dose-response, phase II, multicentre study of radium-223 (Alpharadin TM ) for the palliation of painful bone metastases in hormone refractory prostate cancer patients | ||
Medical condition: The target population is patients suffering from bone pain due to skeletal metastasis secondary to prostate cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: SE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-006022-34 | Sponsor Protocol Number: BAY43-9006/13337 | Start Date*: 2009-01-02 | ||||||||||||||||
Sponsor Name:Bayer HealthCare AG | ||||||||||||||||||
Full Title: Randomized phase II study of sorafenib plus bicaluamide vs. placebo plus bicalutamide in castration-resistant asymptomatic or mildly symptomatic metastatic prostate cancer patients who had orchiect... | ||||||||||||||||||
Medical condition: Metastatic Prostate Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-004749-41 | Sponsor Protocol Number: NEO-ONE | Start Date*: 2011-12-13 | |||||||||||
Sponsor Name:TweeSteden hospital | |||||||||||||
Full Title: The effects of neoadjuvant hormonal therapy on the course of PSA and testosterone in patients with low and intermediate-risk prostate carcinoma (NEO-ONE); A randomized controlled trial | |||||||||||||
Medical condition: Localized prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001365-32 | Sponsor Protocol Number: 19CX5006 | Start Date*: 2019-07-25 | |||||||||||
Sponsor Name:Imperial Joint Research Compliance Office | |||||||||||||
Full Title: IP4- CHRONOS: Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer | |||||||||||||
Medical condition: Prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000314-38 | Sponsor Protocol Number: 1206-HNCG | Start Date*: 2014-07-28 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||
Full Title: A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expre... | |||||||||||||
Medical condition: Salivary gland cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) NL (Completed) GB (GB - no longer in EU/EEA) HU (Completed) AT (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002027-13 | Sponsor Protocol Number: DPSA05 | Start Date*: 2005-07-22 |
Sponsor Name:Royal Marsden NHS FOundation Trust | ||
Full Title: A phase I/II study of docetaxel plus prednisolone plus diethylstilbestrol plus aspirin in androgen-independent prostate cancer | ||
Medical condition: Hormone refractory prostate cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-008604-40 | Sponsor Protocol Number: FE200486 CS31 | Start Date*: 2009-04-09 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: A randomised, parallel-arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of volume reduction of the prostate in patients with pro... | |||||||||||||
Medical condition: Prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) DK (Completed) BE (Completed) PT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-006018-16 | Sponsor Protocol Number: | Start Date*: 2006-02-27 |
Sponsor Name:Royal Marsden Hospital | ||
Full Title: A Randomised Phase III Trial Of Low Dose DailyDexamethasone Versus Intermittent Dexamethasone Versus Prednisolone In Hormone Refractory Prostate Cancer | ||
Medical condition: Hormone refractory prostate cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
